Sector News

Biogen Idec trims R&D staff, looks for new talent in chemistry, neurology

March 14, 2015
Life sciences
Biogen Idec took a look at its R&D group and decided to trim out a small group of its research staffers on Thursday. A spokesperson for the company said today that about 20 staffers were axed following a review of the company’s long-term goals.
 
“There has been no reduction to our R&D workforce,” Biogen ($BIIB) said in a statement sent to FierceBiotech. “As we plan for the future, we took a close look at our chemistry and neurology research teams and determined that some skillsets did not align with our long term goals. Unfortunately, as part of this assessment some employees will be leaving Biogen Idec. We sincerely appreciate their contributions and are taking meaningful steps to support their transition and help them find their next career opportunity.
 
“We plan to hire new employees in both areas to ensure we have the right capabilities to execute on our longterm strategy.”
 
Word of the layoffs first circulated on Derek Lowe’s influential blog, In the Pipeline, on Thursday afternoon.
 
A spokesperson declined to say just how many R&D workers there are at Biogen Idec, but the company as a whole has a workforce of more than 7,500.
 
Biogen has been growing its operation around Kendall Square, where CEO George Scangos moved soon after taking the helm close to 5 years ago. And by all accounts, it’s been a period of growth and success, in the clinic and on the market as the company’s market cap swelled to $95 billion.
 
Biogen Idec’s sales have been surging as its blockbuster MS drug Tecfidera gobbled up market share and the company consolidated its leadership position in MS while gaining new approvals in hemophilia. The company has disappointed Wall Street at times, failing to match analysts’ projections on Tecfidera’s sales growth, but revenue last year jumped to $9.7 billion, a spike from $6.9 billion in 2013.
 
R&D remains interesting at Biogen, with its early-stage Alzheimer’s drug, BIIB037, attracting lots of attention ahead of a conference later this month in which it will more carefully review data. A new drug for remyelination is also in the clinic that’s been attracting considerable attention. R&D costs jumped from $1.4 billion to $1.9 billion, which was 17% of product revenue, not out of line with what Wall Street would expect.
 
By John Carroll
 

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.